Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00353379 · ClinicalTrials.gov registry record · Phase 4
Pharmacology of Cognition in Schizotypal Personality Disorder
A Phase 4 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 4
- Development phase
- 29
- Enrollment target
NCT00353379 is a Phase 4 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 29 participants.
The verdict
NCT00353379, a Phase 4 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of guanfacine in improving cognitive and functional impairments in schizotypal personality disorder.
Interventions
- DRUG Placebo
- DRUG Guanfacine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 1995-09 |
| Est. Completion | 1997-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00353379
The ClinicalTrials.gov registry entry for NCT00353379 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00353379 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00353379 about?
NCT00353379 is a clinical study titled "Pharmacology of Cognition in Schizotypal Personality Disorder". This study will determine the effectiveness of guanfacine in improving cognitive and functional impairments in schizotypal personality disorder.
What is the current status of trial NCT00353379?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 29 participants. The study started on 1995-09. Estimated completion is 1997-05.
What interventions are being tested in trial NCT00353379?
The interventions under investigation include: Placebo (DRUG), Guanfacine (DRUG).
Who is sponsoring clinical trial NCT00353379?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.